ESSA Pharma to acquire Realm Therapeutics

16 May 2019

ESSA Pharma (Nasdaq and TSX-V: EPI) has entered into a definitive agreement with Realm Therapeutics (Nasdaq: RLM) setting forth the terms of an acquisition whereby ESSA will acquire all of the issued and outstanding shares of Realm in an all-stock transaction.

The acquisition, subject inter alia to Realm Shareholder approval, is intended to be implemented by means of a UK Court-sanctioned scheme of arrangement under Part 26 of the UK Companies Act 2006 and is expected to be completed by mid-year 2019.

Upon the closing of the acquisition, the company will continue to operate as ESSA Pharma trade on the Nasdaq Capital Market and TSX-V Market and operate in the USA as ESSA Pharmaceuticals Corp, a Houston, TX-registered wholly-owned subsidiary. The company will focus on advancing ESSA's pipeline of novel potential treatments for prostate and other cancers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK